myasthenia gravis association
MGA
of the heartland

STRENGTH AND CONNECTIONS HOPE THROUGH

VOL. 66 ISSUE 2

MYASTHENIA GRAVIS ASSOCIATION NEWSLETTER

INSIDE THIS ISSUE

Last Call to Register!

Help us raise awareness for Myasthenia Gravis at the 15th Annual MGA Triple Crown Showdown 5K Run/Walk and Mile Mosey & Tot Trot

SIGN UP HERE!

Register Today!
at www.mga5k.com

Race Day
Date: Sunday May 3, 2026
Time: 8:00 am, CT
Location: Town Center Plaza, Leawood, KS

Packet Pick-Up
Date: Saturday May 2, 2026
Time: 10:00 am - 2:00 pm

Date: Sunday, May 3, 2026
Time: Starting at 7:00 am

Location: Town Center Plaza, Leawood, KS

TOWN CENTER PLAZA • LEAWOOD, KS

MEET KATARINA EADS | OUTREACH SPECIALIST

We are excited to introduce Katarina Eads as the newest Outreach Specialist at the Myasthenia Gravis Association. Katarina brings a strong passion for connection and service, shaped by her background in education, her time teaching at a nonprofit school, and her experience serving in the Peace Corps.

Read more about Katarina and what else is new at the MGA on page 9.

HELP US SHARE YOUR MYASTHENIA GRAVIS JOURNEY

SHARE YOUR STORY

SUBMISSIONS

Want to share your MG story or have a topic you would like to see covered? We have multiple ways for you to connect with the MG community! Email Kathryn at kathrynclemens@mgakc.org

FOLLOW US

Follow us: @themgassociation
Instagram | Facebook | YouTube

mgassociation.org

A MESSAGE FROM ALLISON

Adapting Passion: Life with MG

One of my passions as a child was reading. In fact, our family even took vacations that included some storybook characters. Prince Edward Island in Canada to see the homestead of Anne of Green Gables and a trip through South Dakota to stop at a Little House on the Prairie site are memories I cherish from my childhood.

As I moved through college and even right out of college I loved reading. In fact, I was a member of a book club when I lived in Dallas and then in Kansas City. However, at some point as my career became more demanding and I was working long hours, the obviousness of the weakness in my eyes robbed of normal strength due to myasthenia gravis (MG) became too much to withstand reading after a long day. Coupled with the fact that it often was too physically difficult to hold a book and read at night. I lost passion. I went for several years without touching a book. It became a joke on my yearly beach vacation that I would carry around the same book that I brought the year before and never open let alone finish.

Last year, I had a bit of an "aha" moment. Why wasn't I utilizing audio books when I was in the car or on my walking pad in my ear buds? I quickly downloaded and started using the Audible app, playing books through my Bluetooth in the car when traveling and earbuds other places. Here we are a year an a half later, and I am rich in the space of having enjoyed so many audible books. My passion is back! I can't wait to throw in my earbuds after a long day and tune out the world. I have listened and enjoyed so many stories about other people's lives including one of my favorite listens, Ina Garten's memoir, "Be Ready When the Luck Happens" to finally hearing Glennon Doyle's "Untamed" and "We Can Do Hard Things." And lastly, still chewing on the "Let Them" theory by Mel Robbins.

My point in sharing this is to remind you that everything in life can be adapted or tweaked. It can feel like MG is robbing you of many passions, however the important thing is to evaluate what you can tweak so you don't lose that passion. It's amazing the weight that is lifted on your shoulders when you can reignite a passion.

Have a good read to share? I'd love to hear it.

Allison K. Foss

Allison K. Foss | Executive Director | allisonfoss@mgakc.org

CONTACT
816-256-4100
info@mgakc.org

Two targeted treatments for adults with **generalized myasthenia gravis (gMG)**

UCB is committed to making a difference for people living with gMG by providing two treatment options

Is it time to rethink your current gMG therapy?

For people with gMG, symptoms present themselves differently in each diagnosed individual. While most people have fluctuating muscle weakness and fatigue, these symptoms vary from person to person and can range from mild to severe.

UCB offers two treatments that target different aspects of immune function related to gMG and have different methods of administration.

Scan to explore two distinct treatments that allow you and your doctor to choose the gMG treatment that fits your needs.

UCB OFFERS TWO TREATMENTS THAT TARGET gMG DIFFERENTLY:

An FcRn blocker

Harmful antibodies that cause gMG may stay in your body longer because of FcRn (neonatal Fc receptor).

A C5 inhibitor

Harmful anti-AChR antibodies activate part of your immune system called "complement," which works to attack your muscle cells.

Targeted treatments. More options.

Ask your doctor how a targeted therapy may help you meet your gMG treatment goals.

Learn more at **UCBforGMG.com**

Inspired by **patients.**
Driven by **science.**

YOUR VOICE, YOUR POWER

STEP THERAPY: WHAT MG PATIENTS NEED TO KNOW AND HOW TO TAKE ACTION

For individuals living with myasthenia gravis (MG), timely access to the right treatment can make a significant difference in daily function and quality of life. However, many patients encounter an unexpected barrier called step therapy, also known as "fail first," when trying to access prescribed medications.

Understanding Step Therapy:

What is Step Therapy?
Step therapy is a policy used by insurance companies that requires patients to try one or more lower-cost medications before approving coverage for the treatment originally prescribed by their physician. In other words, patients must "fail" on certain medications before moving on to the therapy their doctor recommended.

Why Do Insurance Companies Use It?
Insurance providers use step therapy as a cost-control measure. By requiring patients to try less expensive treatments first, insurers aim to reduce overall healthcare spending. While this approach may work in some cases, it can be problematic for individuals with complex or rare conditions like MG, where not all treatments are interchangeable and delays can worsen symptoms.

The Impact on Individuals with MG

For those living with MG, step therapy can lead to:

- Delays in receiving effective treatment
- Increased symptoms or disease progression
- Additional physical and emotional stress
- More frequent healthcare visits or hospitalizations

Because MG symptoms can fluctuate and worsen quickly, trying and failing medications that may not be appropriate can place an unnecessary burden on patients.

What Happens After a Denial?
Many patients are unaware that a denial is not the end of the road. If a medication is denied due to step therapy, patients and providers can request an exception or appeal.

However, not all providers are familiar with the appeals process, which can make this step feel overwhelming. Appeals typically require documentation explaining why the prescribed treatment is medically necessary and why alternative therapies may not be appropriate.

Step Therapy Exceptions

There are situations where step therapy can be bypassed. Common exceptions include:

- The required medication has already been tried and was ineffective
- The alternative drug could cause harm or worsen the condition
- The patient is stable on their current medication
- The delay could lead to serious health consequences

YOUR VOICE, YOUR POWER

STEP THERAPY: LEGISLATION AND ADVOCACY EFFORTS

Legislation and Advocacy Efforts

State Protections Vary

Some states have enacted laws that require insurance companies to provide a clear and timely exceptions process. These laws may include:

- Defined timelines for insurance responses
- Clear criteria for granting exceptions
- Protections to prevent unnecessary delays

However, not all states have these protections in place, which means access to care can depend heavily on where a patient lives.

How You Can Get Involved

Patients, caregivers, and advocates play a vital role in improving these policies. You can:

- Share your personal experience with step therapy
- Contact your state and federal representatives
- Support advocacy organizations working on this issue
- Stay informed about legislation impacting access to care
-

Your voice can help drive change and improve access for others in the MG community.

Legislation and Advocacy Efforts

National advocacy organizations, including the National Organization for Rare Disorders, are working to improve step therapy policies.

Efforts focus on:

- Standardizing exception processes
- Reducing delays in treatment approval
- Ensuring physicians have greater authority in treatment decisions

At the federal level, proposed legislation such as the H.R. 5509 (Safe Step Act) aims to strengthen these protections by requiring health plans to implement clear and timely exceptions processes. If enacted, this legislation would help ensure that patients can access medically necessary treatments without prolonged delays caused by step therapy requirements.

There is ongoing work at both the state and federal levels to strengthen these protections and ensure patients with rare diseases receive timely, appropriate care.

Final Thoughts

Step therapy can be a confusing and frustrating barrier, but understanding your rights and options is an important first step. If you receive a denial, know that appeals and exceptions exist—and support is available to help guide you through the process.

Beyond AChR
CLOSING THE GAPS
in MG Treatment

In recent years, the treatment landscape for myasthenia gravis (MG) has changed dramatically. New, targeted therapies are offering hope to many individuals living with MG, bringing more effective options and improved quality of life.

However, while this progress is exciting, it has also highlighted important gaps—especially for those living with seronegative MG and ocular MG, who have historically had fewer treatment options.

Progress: A New Era of Targeted Therapies

For many years, MG treatment relied heavily on broad immunosuppressants. Today, newer therapies are designed to target specific parts of the immune system, leading to more precise and often more effective treatment.

Medications such as FcRn inhibitors and complement inhibitors have transformed care for many patients. These therapies were initially approved for individuals who are anti-acetylcholine receptor (AChR) antibody positive, but that is beginning to change.

Pharmaceutical companies are now actively working to expand these treatments to include a broader range of individuals with MG.

Expanding Access: Beyond AChR-Positive MG

One of the most significant advancements is the push to expand treatment approvals beyond AChR-positive patients.

For example, Vyvgart (efgartigimod) is currently under review for use in seronegative generalized MG, following clinical trial results showing meaningful improvement across multiple subtypes, including MuSK-positive and triple seronegative patients. If approved, this would mark a major shift toward making targeted therapies accessible regardless of antibody status.

Similarly, newer therapies like IMAAVY™ (nipocalimab) are being developed with broader patient populations in mind from the start, signaling a move toward more inclusive treatment options.

Ocular MG: Long Overlooked, Now in Focus

Ocular MG, which primarily affects vision, has long been treated using the same approaches as generalized MG—without therapies specifically approved for it.

That may soon change.

A recent Phase 3 trial (ADAPT-OCULUS) studying efgartigimod in ocular MG showed promising results, potentially paving the way for the first targeted therapy approved specifically for this group. This marks an important step in recognizing ocular MG as a distinct condition with unique treatment needs.

Closing the Gaps in MG Treatment, continued

Where Gaps Still Remain

Despite this progress, challenges remain.

- Many newer therapies are still not yet approved for all MG subtypes
- Patients with seronegative MG may still face delays in access
- Ocular MG treatments are still in the approval process
- Insurance barriers, including step therapy, can further delay care

These gaps can lead to frustration, prolonged symptoms, and difficulty finding the right treatment.

Looking Ahead

The direction of MG treatment is clear: moving from narrow, highly specific approvals toward broader, more inclusive therapies.

This shift has the potential to:

- Improve access to effective treatments
- Reduce trial-and-error approaches
- Ensure more patients receive care tailored to their needs

Final Thoughts

The progress in MG treatment over the past few years is remarkable. For many, these advancements have been life-changing. At the same time, it is important to continue advocating for expanded access, increased awareness, and continued research—so that all individuals living with MG, regardless of subtype, can benefit from these innovations.

MG CLINICAL TRIAL UPDATES

University of Kansas Medical Center

MyClad PI: Dr. Mamatha Pasnoor
ClinicalTrials.gov Identifier: NCT06463587
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

For more information contact: Samantha Colgan, scolgan@kumc.edu

AURORA PI: Cartesian Therapeutics ClinicalTrials.gov Identifier: NCT06799247
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)

For more information contact: Nora Khalifa, nkhalifa@kumc.edu

RemeMG PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06456580
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

For more information: Courtney Richardson, c969r831@kumc.edu

KATALYST MG PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06064695
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

For more information for the KU trial location contact: Abby Davis, adavis54@kumc.edu

ARGX-113-2315 PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06298565
A non-interventional, post-authorisation safety study of patients treated with efgartigimod alfa

For more information contact: Lilli Saavedra, lsaavedra2@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06359041
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants with Generalized Myasthenia Gravis

For more information: Lillian Saavedra, lsaavedra2@kumc.edu

COUR Pharma PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06106672
A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP–106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
Experimental: ALXN1720

For more information contact: Abby Davis, adavis54@kumc.edu

MG CLINICAL TRIAL UPDATES

University of Missouri

NMD Pharma PI: University of Missouri- Columbia
ClinicalTrials.gov Identifier: NCT06414954
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

For more information contact: Neetha Gali, ngdcd@health.missouri.edu

COUR Pharma - MG PI: University of Missouri- Columbia ClinicalTrials.gov Identifier: NCT06106672
A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP–106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
Experimental: ALXN1720

For more information contact: Neetha Gali, ngdcd@health.missouri.edu

SPONSORED CONTENT

CAN YOU MAKE AN IMPACT IN MYASTHENIA GRAVIS (MG) RESEARCH?

MYCLAD

The MyClad Study is researching an investigational medication taken by mouth for generalized myasthenia gravis (gMG) and is now enrolling. Join us.

The MyClad Study is looking to learn more about an investigational medication taken by mouth regarding its safety and ability to treat people with gMG. The investigational medication will be given as a capsule to be swallowed. We want to evaluate the ability to improve your gMG symptoms when using the investigational medication.

You may be eligible for this study if you:

- are an adult of at least 18 years of age or older
- have a confirmed diagnosis of MG with generalized muscle weakness.

Your doctor will review the study requirements and discuss your eligibility with you.

You will receive all study-related procedures and the investigational medication at no cost.

Study participation will last for about 3 years.

This study has been designed with gMG patients' feedback and reviewed by an Institutional Review Board (IRB)/Ethics Committee (EC), which protects the rights, safety, and well-being of the participants.

To learn more, ask your doctor about the MyClad Study or scan the QR code.

mycladstudy.com

EMD SERONO

Sponsored Content, 05 Sep 2025 [V01 USA(en)]

The SYNAPSE-MG Clinical trial
for generalized Myasthenia Gravis (gMG)

An investigational study evaluating a **potential new oral treatment for MG** that allows participants to remain on their current medications.*

Who's eligible?

Thosewith a confirmed diagnosis of gMG with AChR or MuSK autoantibodies, along with other key eligibility requirements:

- ✓ **18–75 years old**
- ✓ **Able to take oral tablets**
- ✓ **Able to attend in-person clinic visits over an 8-week time period**

NMDPHARMA® NEUROMUSCULAR DISORDERS | CLINICAL TRIALS

*For many patients, most gMG medications can be continued exactly as they are currently being taken

For more information about the clinical trial scan the QR code or visit NMD Pharma's Clinical Trial website
nmdclinicaltrials.com/clinical-trials/synapse-mg/

See WHAT'S NEW At the MGA

Meet Katarina Eads | Outreach Specialist

We are excited to introduce Katarina Eads as the newest Outreach Specialist at the Myasthenia Gravis Association. Katarina brings a strong passion for connection and service, shaped by her background in education, her time teaching at a nonprofit school, and her experience serving in the Peace Corps.

Her journey has always been guided by a desire to make a meaningful impact. Through her work and life experiences, Katarina has developed a deep appreciation for community, shared understanding, and the importance of human connection—values that align closely with the mission of the MGA.

Katarina was drawn to the MGA through her personal experiences supporting family members living with chronic illness. Seeing firsthand the challenges families face, she understands the importance of having a strong support system and meaningful resources. She is especially inspired by the way the MGA fosters real relationships and creates spaces where individuals feel seen, supported, and connected.

In her role, Katarina is most looking forward to building relationships, learning from the MG community, and helping create an environment where individuals and families feel supported every step of the way.

Outside of work, Katarina enjoys teaching yoga and hiking—activities that allow her to slow down, stay present, and connect with others and the world around her. She also loves travel and embraces new challenges, including a memorable solo trip to Spain.

We are thrilled to have Katarina as part of the MGA team and look forward to the impact she will make within our community.

Welcome to Our Medical Advisory Committee

Tania Beltran Papsdorf, M.D.

We are pleased to welcome Tania Beltran Papsdorf, M.D. to the Myasthenia Gravis Association's Medical Advisory Committee. Dr. Papsdorf provides hospital care for patients with stroke and other neurological disorders at Lake Regional Health System and also supports individuals living with myasthenia gravis through MGA clinic visits. She is board certified in both psychiatry and neurology and brings a wealth of knowledge and experience to our team.

With a background that includes years of collaboration with the MGA, Dr. Papsdorf has demonstrated a strong commitment to supporting individuals with rare conditions. She is passionate about guiding patients through complex and challenging diagnoses with compassion and expertise.

We are honored to have Dr. Papsdorf join our advisory committee and look forward to the impact she will make in our community.



WHERE IN THE WORLD IS THE MGA?

Rare Disease Clinical Research Network (RDCRN) | Semi-Annual Meeting Washington, DC
In February, McKenna Fulton, Community Program Coordinator in Kansas City, has been in Washington, DC attending the Semi-Annual RDCRN Meeting alongside other rare disease organizations.

Rare Disease Day Symposium WashU | St. Louis, MO
In February, Kathryn Clemens, Community Program Coordinator in St. Louis, provided an MGA booth at Washington University's Annual Rare Disease Day Symposium.

Rare KC Rare Disease Day Event | Kansas City, MO
in March, Halle Walker, our Event Coordinator, attended Rare KC's Rare Disease Day Event.

Wichita State University Health Fair | Wichita, KS
In March, our Wichita Support Group attended and provided a booth at Wichita State University's Health Fair.

MDA Clinical & Scientific Conference | Orlando, FL
In March, Kathryn Clemens, Community Program Coordinator in St. Louis, provided a booth at the Annual Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

EXPLORE THE POSSIBILITIES

Ask your doctor about VYVGART Hytrulo (efgartigamod alfa and hyaluronidase-qvfc) and VYVGART (efgartigamod alfa-fcab)

VYVGART® Hytrulo	VYVGART®
(efgartigimod alfa and hyaluronidase-qvfc)	(efgartigimod alfa-fcab)
Subcutaneous Injection 180 mg/mL and 2000 U/mL vial	Injection for Intravenous Use 400 mg/20 mL vial

Scan the QR code or visit VYVGART.com to learn more

Questions? Call 1-833-VYVGART (1-833-898-4278)

argenx

UPCOMING EVENTS

CROWN TOWN TRIVIA NIGHT

JULY 31, 2026

For the first time ever, the FIFA World Cup is being held in Kansas City! To celebrate, we are excited to switch up our location for our annual Trivia Night.

Join us for a night like no other and discover opportunities on how to get involved! We are excited to switch up our location, bringing you a once in a lifetime experience following the FIFA World Cup in Kansas City!

More details coming soon via email!
Stay informed: www.mgassociation.org

CROWN TOWN
TRIVIA NIGHT

Date: July 31, 2026
Time: 6:30 - 10:00 pm
Location: Sporting Park, Sporting KC
1 Sporting Way, Kansas City, KS

Snowflake Saturday

WICHITA
MGA SNOWFLAKE SATURDAY

Date: June 6, 2026
Time: 10:00 am - 1:00 pm
Location: Chicken N Pickle - Wichita
1240 N Greenwich Rd, Wichita, KS 67206

IOWA
MGA SNOWFLAKE SATURDAY

Date: June 13, 2026
Time: 10:00 am - 1:00 pm
Location: Hilton Garden Inn Des Moines/Urbandale
8600 Northpark Dr, Johnston, IA 50131

We are excited to continue last year's awareness event which will include FREE entry for all attendees! Although you MUST be registered to attend. Attendees will enjoy a catered lunch, vendor booths by our industry partners, and hear from Julie Wells with Give an Hour. There will be the opportunity to purchase MGA swag and raffle tickets!

SCAN HERE

Register for **WICHITA** here!

Register for **IOWA** here!

SCAN HERE

UPCOMING EVENTS

Myasthenia Gravis Association
5K • Mile Mosey • Tot Trot
TRIPLE CROWN
SHOWDOWN
May 3, 2026
15th Anniversary

5K RUN/WALK & TOT TROT

Date: Sunday, May 3, 2026
Time: 8:00 am, CT
Location: Town Center Plaza, Leawood, KS

PACKET PICK-UP

Date: Saturday, May 2, 2026
Time: 10:00 am - 2:00 pm
Location: Town Center Plaza, Leawood, KS

Date: Sunday, May 3, 2026
Time: Starting at 7:00 am
Location: Town Center Plaza, Leawood, KS

Packets will be mailed to those who registered for Stuck in the Stall after the run.

Register at www.mga5k.com

All individuals living with MG register for FREE, email the MGA for the code at info@mgakc.org.

Membership Donations

- Michael and Dororthy Eagan
- Tom Vansahgi
- Al Dimmitt
- Brodie Beck
- Mamatha Pasnoor, MD
- Tom and Melinda Cook
- Derek Haverkamp
- Elana King
- Janice and Steve Katz
- April Zobel
- Shannon Harris, MD
- Nancy Hupp
- Janie Watts & John Rance
- Raymond Phelps
- Richard DeGeorge
- Cindy Disque
- Barbara and Jim Koester in honor of Mike Nervig

In Memoriam

Gordon Goldman in memory of CC Swarens

Thank you

SUPPORT FOR MYASTHENIA GRAVIS (MG)

MORE THAN MG

Find what makes you More Than MG

Join the community of patients, caregivers, and other advocates

Whether you're looking to hear more about MG, find a friend with the same diagnosis, or receive some motivation, there's a place for you in the More Than MG community.

Visit More Than MG to explore:

- Patient stories shared through social media
- Tips for living life beyond an MG diagnosis
- Encouraging reminders and motivation
- Resources for you and your loved ones

MoreThanMG.com ↗

Follow
@MoreThanMG

Use our More Than MG Instagram filter
to help spark awareness about vision impairment.

GO TO @MoreThanMG ON INSTAGRAM
TAP THE SPARKLES ICON
SEE MG SELECT THE "SEE MG" FILTER

DID YOU KNOW MG CAN CAUSE DOUBLE VISION?
Visit @morethanmg for myasthenia gravis (MG) support

ALEXION
AstraZeneca Rare Disease

Find A SUPPORT GROUP Near you

Arkansas

Arkansas Support Group
Quarterly Saturday | 10:00 - 11:30 am | Hybrid: Zoom or In-Person at Springdale Public Library, 405 S. Pleasant St. Springdale, AR
Open to individuals, caregivers & providers
Next Meeting – April 25, 2026
RSVP: kathrynclemens@mgakc.org

Iowa

Iowa Support Group
Bi-Monthly on the 2nd Wednesday | 6:00 - 7:00 pm | Kirkendall Public Library
1250 SW District Dr, Ankeny IA
Open to individuals, caregivers & providers
Hosted by Katie Coffman, Volunteer Support Group Leader
Next Meeting – June 13, 2026 (Snowflake Saturday - Hilton Garden Inn Des Moines/Urbandale)
August 12, 2026
RSVP: katarinaeads@mgakc.org

Kansas

Kansas City Coffee Club
1st Thursday of the month | 9:30 - 10:30 am
Urban Egg, 4921 W 119th St, Overland Park, KS
Coffee is Dutch treat | Open to individuals, caregivers & providers
Hosted by Janice Katz & Melissa Lathrop, Volunteer Support Group Leaders
Next Meeting – May 7, 2026 | June 4, 2026
RSVP: info@mgakc.org

Lawrence Support Group
Quarterly on a Thursday | 5:30 -7:00 pm | Lawrence Public Library, 707 Vermont Street, Lawrence, KS
Open to individuals, caregivers & providers
Next Meeting – May 28, 2026 | August 27, 2026
RSVP: mckennafulton@mgakc.org

Find A SUPPORT GROUP Near you

Kansas

Wichita Support Group
Quarterly on a Saturday | 2:00 - 4:00 pm | Wichita Public Library,
Alford Branch 3447 S. Meridian St. Wichita, KS
Open to individuals, caregivers & providers
Hosted by Dana Paxson, Volunteer Support Group Leaders
Next Meeting – May 16, 2026
RSVP: katarinaeads@mgakc.org

Missouri

Eastsiders Lunch Bunch - Blue Springs
1st Wednesday of the month | 11:30 am - 1:00 pm
312 SW 19th Terrace Street, Blue Springs, MO
Light lunch provided | Open to individuals, caregivers & providers
Hosted by Carol Hunt & Raymond Hankins, Volunteer Support Group Leaders
Next Meeting - May 6, 2026 | June 3, 2026
RSVP to mckennafulton@mgakc.org

Kansas City Coffee Club
1st Thursday of the month | 9:30 -10:30 am | Urban Egg, 4921 W 119th St, Overland Park, KS
Coffee is Dutch treat | Open to individuals, caregivers & providers
Hosted by Janice Katz & Melissa Lathrop, Volunteer Support Group Leaders
Next Meeting – May 7, 2026 | June 4, 2026
RSVP: info@mgakc.org

Greater Kansas City Support Group
Quarterly on a Saturday | 10:30 am -12:00 pm | St. Joseph Medical Center
1000 Carondelet Dr, Kansas City, MO 64114
Light brunch is provided | Open to individuals, caregivers & providers
Next Meeting — April 18, 2026 | July 18, 2026
RSVP: mckennafulton@mgakc.org

Kansas City Northland Support Group
Jan-Nov, bi-monthly on a Thursday | 12:00 -1:30 pm | Primrose Retirement Community,
8559 N. Line Creek Road, Kansas City, MO
Light lunch is provided | Open to individuals, caregivers & providers
Hosted by Sandy Gardner, Volunteer Support Group Leader
Next Meeting – May 14, 2026
RSVP: mckennafulton@mgakc.org

Find A SUPPORT GROUP Near you

Missouri

St. Joseph Support Group
Bi-Monthly | 2:30 - 4:00 pm | Hazel's Coffee Roasting Company, 3829 Frederick Ave, St Joseph, MO
Open to individuals, caregivers & providers | Coffee is Dutch treat
Hosted by Donna Whittaker, Volunteer Support Group Leader
Next Meeting - June 4, 2026
RSVP: info@mgakc.org

Springfield Support Group
Quarterly on a Thursday | 5:30 - 7:00 pm | East Sunshine Church of Christ
3721 E. Sunshine St , Springfield, MO
Open to individuals, caregivers & providers
Next Meeting – April 23, 2026 | July 23, 2026
RSVP: kathrynclemens@mgakc.org

Mid-Missouri Group
Quarterly on a Thursday | 5:30 -7:00 pm | Shakespeare's Pizza South, 3911 Peachtree Dr, Columbia, MO
Open to individuals, caregivers & providers
Hosted by Jonni Sutton, Volunteer Support Group Leader
Next Meeting – July 9, 2026
RSVP: kathrynclemens@mgakc.org

St. Louis Coffee Club
4th Thursday of the month | 10:30 -11:30 am | St. Louis Bread Company, 10221 Manchester Rd, Kirkwood, MO
Coffee is Dutch treat | Open to individuals, caregivers & providers
Next Meeting – May 28, 2026
RSVP: kathrynclemens@mgakc.org

St. Louis Support Group
Quarterly on a Saturday | 10:00 -11:30 am | Glendale City Hall Auditorium, St. Louis, MO
Light brunch provided | Open to individuals, caregivers & providers
Next Meeting – May 16, 2026
RSVP: kathrynclemens@mgakc.org

Find A SUPPORT GROUP Near you

Nebraska

Omaha Support Group
Bi-Monthly | 2nd Saturday | 10:00 - 11:30 am | Immanuel Hospital (The Centennial Room)
6901 N 72nd St, Omaha, NE 68122
Open to individuals, caregivers & providers
Hosted by Dianna & Ralph McCarty, Volunteer Support Group Leaders
Next Meeting - June 13, 2026
RSVP: katarinaeads@mgakc.org

Virtual

Muscle Makers
3rd Wednesday of the month | 12:30 - 1:30 pm CT | Via Zoom
A virtual community for individuals with MG to bring your hobbies to life. Bring your craft and creativity to your screen while connect with others.
Hosted by Bryan Bosch, Volunteer Support Group Leader
Next Meeting – May 20, 2026 | June 17, 2026
Register at mgassociation.org or email info@mgakc.org

MG Pride Group
Bi– Monthly on a Tuesday | 6:00 - 7:00 pm CT
Via Zoom | Open to individuals who identify as LGTBQ+ with MG, their allies and care partners
Hosted by Bryan Bosch, Volunteer Support Group Leader
Next Meeting – June 2, 2026
RSVP: info@mgakc.org

Virtual Monthly Meetup
4th Monday of the month | 6:30 -7:30 pm CT via Zoom
Open to individuals, caregivers & providers
Next Meeting – April 27, 2026
Register at mgassociation.org or email info@mgakc.org

Young Friends of the MGA– Virtual Support Group
Bi-Monthly via zoom| 5:30 - 6:30 pm CT | Via Zoom
Open to individuals who are generally, in their 20s, 30s and 40s
Next Meeting – May 5, 2026
RSVP: info@mgakc.org

Become a 2026 Member of the MYASTHENIA GRAVIS ASSOCIATION

Cut and enclose in envelope. Mail to MGA address below:

I want to support the MGA by becoming a 2026

☐	$25.00	Basic Member
☐	$64.00	64th Anniversary Member
☐	$100.00	Sustaining Member
☐	$500.00	Patron Member
☐	$1,000.00	Lifetime Member

$________In memory of: ______________________

$________In honor of: ________________________

Name :__________________________________

Address: _________________________________

City, State, Zip:____________________________

Phone:__________________________________

Email: ___________________________________

I am a: ☐ MG PATIENT ☐ RELATIVE ☐ FRIEND ☐ OTHER

MGA
2340 E. Meyer Blvd., Bld. 1, Suite 300A
Kansas City, MO, 64132

-Contributions may be tax deductible

-Make checks payable to:
Myasthenia Gravis Association

Myasthenia Gravis Association
2340 E. Meyer Blvd. Building 1, Suite
300A Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgakc.org
www.mgassociation.org